• Pediatric drug approvals in China have increased significantly, with a focus on rare diseases and oncology.
• Off-label use remains prevalent due to a lack of pediatric-specific formulations and clinical data.
• Regulatory reforms and incentives have accelerated pediatric drug development, but gaps persist.
• International collaboration and harmonized standards are essential for advancing pediatric drug research.